Our top pick for
BridgeBio Pharma Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 385 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$47.00|
|52-week range||$37.29 - $73.50|
|50-day moving average||$48.42|
|200-day moving average||$54.31|
|Wall St. target price||$81.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.76%|
|1 month (2021-09-24)||-3.23%|
|3 months (2021-07-23)||-22.44%|
|6 months (2021-04-23)||-13.71%|
|1 year (2020-10-23)||18.51%|
|2 years (2019-10-25)||151.07%|
|3 years (2018-10-21)||N/A|
|5 years (2016-10-21)||N/A|
|Revenue TTM||$62.7 million|
|Gross profit TTM||$8.2 million|
|Return on assets TTM||-31.81%|
|Return on equity TTM||-1789.67%|
|Market capitalisation||$7 billion|
TTM: trailing 12 months
There are currently 11.0 million BridgeBio Pharma shares held short by investors – that's known as BridgeBio Pharma's "short interest". This figure is 4.9% down from 11.5 million last month.
There are a few different ways that this level of interest in shorting BridgeBio Pharma shares can be evaluated.
BridgeBio Pharma's "short interest ratio" (SIR) is the quantity of BridgeBio Pharma shares currently shorted divided by the average quantity of BridgeBio Pharma shares traded daily (recently around 1.0 million). BridgeBio Pharma's SIR currently stands at 10.78. In other words for every 100,000 BridgeBio Pharma shares traded daily on the market, roughly 10780 shares are currently held short.
However BridgeBio Pharma's short interest can also be evaluated against the total number of BridgeBio Pharma shares, or, against the total number of tradable BridgeBio Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BridgeBio Pharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 BridgeBio Pharma shares in existence, roughly 70 shares are currently held short) or 0.1332% of the tradable shares (for every 100,000 tradable BridgeBio Pharma shares, roughly 133 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BridgeBio Pharma.
Find out more about how you can short BridgeBio Pharma stock.
We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.
Over the last 12 months, BridgeBio Pharma's shares have ranged in value from as little as $37.29 up to $73.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BridgeBio Pharma's is 0.7808. This would suggest that BridgeBio Pharma's shares are less volatile than average (for this exchange).
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.